DK2026073T3 - Diagnostik og behandling af makuladegeneration-relaterede forstyrrelser - Google Patents

Diagnostik og behandling af makuladegeneration-relaterede forstyrrelser Download PDF

Info

Publication number: DK2026073T3
Authority: DK; Denmark
Prior art keywords: complement; vol; macular degeneration; rpe; pathway
Prior art date: 2000-04-29

Application number

DK08162987.5T

Other languages

English (en)

Inventor

Gregory S Hageman

Robert F Mullins

Original Assignee

Univ Iowa Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-29

Filing date

2001-04-30

Publication date

2016-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22742799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2026073(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-30 Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found

2016-07-25 Application granted granted Critical

2016-07-25 Publication of DK2026073T3 publication Critical patent/DK2026073T3/da

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 161
208000002780 macular degeneration Diseases 0.000 title claims abstract description 141
238000003745 diagnosis Methods 0.000 title description 15
238000000034 method Methods 0.000 claims abstract description 235
230000000295 complement effect Effects 0.000 claims description 94
210000003583 retinal pigment epithelium Anatomy 0.000 claims description 89
230000002159 abnormal effect Effects 0.000 claims description 64
238000012360 testing method Methods 0.000 claims description 58
230000014509 gene expression Effects 0.000 claims description 47
201000010099 disease Diseases 0.000 claims description 45
210000002966 serum Anatomy 0.000 claims description 45
150000007523 nucleic acids Chemical class 0.000 claims description 40
102000039446 nucleic acids Human genes 0.000 claims description 36
108020004707 nucleic acids Proteins 0.000 claims description 36
210000004369 blood Anatomy 0.000 claims description 24
239000008280 blood Substances 0.000 claims description 24
238000001514 detection method Methods 0.000 claims description 21
108020004999 messenger RNA Proteins 0.000 claims description 20
230000006378 damage Effects 0.000 claims description 19
210000002381 plasma Anatomy 0.000 claims description 19
239000012530 fluid Substances 0.000 claims description 17
230000035772 mutation Effects 0.000 claims description 16
210000002700 urine Anatomy 0.000 claims description 15
239000012472 biological sample Substances 0.000 claims description 13
238000012217 deletion Methods 0.000 claims description 9
230000037430 deletion Effects 0.000 claims description 9
206010064930 age-related macular degeneration Diseases 0.000 claims description 7
239000002299 complementary DNA Substances 0.000 claims description 6
230000037433 frameshift Effects 0.000 claims description 5
230000003827 upregulation Effects 0.000 claims description 5
231100000221 frame shift mutation induction Toxicity 0.000 claims description 4
230000024203 complement activation Effects 0.000 description 216
108090000623 proteins and genes Proteins 0.000 description 158
208000035475 disorder Diseases 0.000 description 111
102000004169 proteins and genes Human genes 0.000 description 110
235000018102 proteins Nutrition 0.000 description 107
210000004027 cell Anatomy 0.000 description 74
108010034753 Complement Membrane Attack Complex Proteins 0.000 description 72
230000037361 pathway Effects 0.000 description 64
230000000694 effects Effects 0.000 description 63
239000003795 chemical substances by application Substances 0.000 description 59
150000001875 compounds Chemical class 0.000 description 44
239000003814 drug Substances 0.000 description 43
210000001775 bruch membrane Anatomy 0.000 description 42
241000282414 Homo sapiens Species 0.000 description 41
238000003556 assay Methods 0.000 description 40
230000004154 complement system Effects 0.000 description 40
210000001519 tissue Anatomy 0.000 description 38
230000004913 activation Effects 0.000 description 37
210000003161 choroid Anatomy 0.000 description 37
210000000411 amacrine cell Anatomy 0.000 description 36
210000001508 eye Anatomy 0.000 description 34
230000027455 binding Effects 0.000 description 30
230000007850 degeneration Effects 0.000 description 29
108090000765 processed proteins & peptides Proteins 0.000 description 28
239000000047 product Substances 0.000 description 28
102100022133 Complement C3 Human genes 0.000 description 26
101000901154 Homo sapiens Complement C3 Proteins 0.000 description 26
230000001413 cellular effect Effects 0.000 description 26
102000004196 processed proteins & peptides Human genes 0.000 description 26
102100031506 Complement C5 Human genes 0.000 description 25
102100035140 Vitronectin Human genes 0.000 description 25
229940124597 therapeutic agent Drugs 0.000 description 25
108010031318 Vitronectin Proteins 0.000 description 24
150000001413 amino acids Chemical class 0.000 description 24
101000941598 Homo sapiens Complement C5 Proteins 0.000 description 23
230000001404 mediated effect Effects 0.000 description 23
239000000427 antigen Substances 0.000 description 22
102000003780 Clusterin Human genes 0.000 description 21
108090000197 Clusterin Proteins 0.000 description 21
108091007433 antigens Proteins 0.000 description 21
102000036639 antigens Human genes 0.000 description 21
210000004379 membrane Anatomy 0.000 description 21
239000012528 membrane Substances 0.000 description 21
239000000523 sample Substances 0.000 description 21
102000000989 Complement System Proteins Human genes 0.000 description 20
108010069112 Complement System Proteins Proteins 0.000 description 20
108060003951 Immunoglobulin Proteins 0.000 description 20
238000004458 analytical method Methods 0.000 description 20
230000002068 genetic effect Effects 0.000 description 20
102000018358 immunoglobulin Human genes 0.000 description 20
230000008569 process Effects 0.000 description 20
210000001525 retina Anatomy 0.000 description 19
201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 description 18
208000037312 Familial drusen Diseases 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
235000001014 amino acid Nutrition 0.000 description 18
108020004414 DNA Proteins 0.000 description 17
201000006754 cone-rod dystrophy Diseases 0.000 description 16
239000010410 layer Substances 0.000 description 16
230000002207 retinal effect Effects 0.000 description 16
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 16
102000016574 Complement C3-C5 Convertases Human genes 0.000 description 15
108010067641 Complement C3-C5 Convertases Proteins 0.000 description 15
239000003550 marker Substances 0.000 description 15
238000005259 measurement Methods 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 14
239000012634 fragment Substances 0.000 description 14
230000006870 function Effects 0.000 description 14
210000004443 dendritic cell Anatomy 0.000 description 13
238000011161 development Methods 0.000 description 13
230000018109 developmental process Effects 0.000 description 13
238000002405 diagnostic procedure Methods 0.000 description 13
230000001965 increasing effect Effects 0.000 description 13
239000000126 substance Substances 0.000 description 13
108090000056 Complement factor B Proteins 0.000 description 12
108010087870 Mannose-Binding Lectin Proteins 0.000 description 12
239000003112 inhibitor Substances 0.000 description 12
230000001105 regulatory effect Effects 0.000 description 12
239000007790 solid phase Substances 0.000 description 12
102100022002 CD59 glycoprotein Human genes 0.000 description 11
238000002965 ELISA Methods 0.000 description 11
206010025421 Macule Diseases 0.000 description 11
-1 and MASP-2) Proteins 0.000 description 11
238000009826 distribution Methods 0.000 description 11
229920001184 polypeptide Polymers 0.000 description 11
102000003712 Complement factor B Human genes 0.000 description 10
102100030886 Complement receptor type 1 Human genes 0.000 description 10
101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 10
102000009112 Mannose-Binding Lectin Human genes 0.000 description 10
102100026553 Mannose-binding protein C Human genes 0.000 description 10
230000003213 activating effect Effects 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
239000000284 extract Substances 0.000 description 10
230000004054 inflammatory process Effects 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
239000000203 mixture Substances 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
238000012216 screening Methods 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
206010061218 Inflammation Diseases 0.000 description 9
102000004856 Lectins Human genes 0.000 description 9
108090001090 Lectins Proteins 0.000 description 9
108091034117 Oligonucleotide Proteins 0.000 description 9
208000027073 Stargardt disease Diseases 0.000 description 9
210000000170 cell membrane Anatomy 0.000 description 9
238000003776 cleavage reaction Methods 0.000 description 9
230000002255 enzymatic effect Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
238000002372 labelling Methods 0.000 description 9
239000002523 lectin Substances 0.000 description 9
108091008695 photoreceptors Proteins 0.000 description 9
230000004044 response Effects 0.000 description 9
230000007017 scission Effects 0.000 description 9
102000004506 Blood Proteins Human genes 0.000 description 8
108010074051 C-Reactive Protein Proteins 0.000 description 8
102100032752 C-reactive protein Human genes 0.000 description 8
108010053085 Complement Factor H Proteins 0.000 description 8
102000016550 Complement Factor H Human genes 0.000 description 8
102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 8
108010042484 Mannose-Binding Protein-Associated Serine Proteases Proteins 0.000 description 8
210000001744 T-lymphocyte Anatomy 0.000 description 8
239000005557 antagonist Substances 0.000 description 8
230000000692 anti-sense effect Effects 0.000 description 8
230000034994 death Effects 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
238000001476 gene delivery Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
210000000265 leukocyte Anatomy 0.000 description 8
239000011159 matrix material Substances 0.000 description 8
238000012163 sequencing technique Methods 0.000 description 8
230000014616 translation Effects 0.000 description 8
238000001262 western blot Methods 0.000 description 8
208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 7
108010017384 Blood Proteins Proteins 0.000 description 7
102100032768 Complement receptor type 2 Human genes 0.000 description 7
206010018364 Glomerulonephritis Diseases 0.000 description 7
102000014702 Haptoglobin Human genes 0.000 description 7
108050005077 Haptoglobin Proteins 0.000 description 7
208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 7
208000016113 North Carolina macular dystrophy Diseases 0.000 description 7
208000034247 Pattern dystrophy Diseases 0.000 description 7
201000007737 Retinal degeneration Diseases 0.000 description 7
208000022758 Sorsby fundus dystrophy Diseases 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000000470 constituent Substances 0.000 description 7
210000002744 extracellular matrix Anatomy 0.000 description 7
210000002287 horizontal cell Anatomy 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
238000003752 polymerase chain reaction Methods 0.000 description 7
230000004258 retinal degeneration Effects 0.000 description 7
230000009870 specific binding Effects 0.000 description 7
201000007790 vitelliform macular dystrophy Diseases 0.000 description 7
208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 7
108010089414 Anaphylatoxins Proteins 0.000 description 6
102100029470 Apolipoprotein E Human genes 0.000 description 6
101710095339 Apolipoprotein E Proteins 0.000 description 6
206010018910 Haemolysis Diseases 0.000 description 6
101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
208000002678 Mucopolysaccharidoses Diseases 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
206010038848 Retinal detachment Diseases 0.000 description 6
230000005856 abnormality Effects 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
230000004064 dysfunction Effects 0.000 description 6
230000008588 hemolysis Effects 0.000 description 6
230000002949 hemolytic effect Effects 0.000 description 6
229940072221 immunoglobulins Drugs 0.000 description 6
230000000977 initiatory effect Effects 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
238000010369 molecular cloning Methods 0.000 description 6
238000012544 monitoring process Methods 0.000 description 6
206010028093 mucopolysaccharidosis Diseases 0.000 description 6
210000000440 neutrophil Anatomy 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
230000002265 prevention Effects 0.000 description 6
230000004264 retinal detachment Effects 0.000 description 6
201000000596 systemic lupus erythematosus Diseases 0.000 description 6
201000001320 Atherosclerosis Diseases 0.000 description 5
108010055167 CD59 Antigens Proteins 0.000 description 5
208000005590 Choroidal Neovascularization Diseases 0.000 description 5
206010060823 Choroidal neovascularisation Diseases 0.000 description 5
102100025680 Complement decay-accelerating factor Human genes 0.000 description 5
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
241000282412 Homo Species 0.000 description 5
101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 5
108700028909 Serum Amyloid A Proteins 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
239000000556 agonist Substances 0.000 description 5
230000003321 amplification Effects 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
230000008436 biogenesis Effects 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
230000007812 deficiency Effects 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
238000003018 immunoassay Methods 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
230000002055 immunohistochemical effect Effects 0.000 description 5
238000010324 immunological assay Methods 0.000 description 5
MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 5
229960004657 indocyanine green Drugs 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
230000035699 permeability Effects 0.000 description 5
108091033319 polynucleotide Proteins 0.000 description 5
102000040430 polynucleotide Human genes 0.000 description 5
239000002157 polynucleotide Substances 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
238000013519 translation Methods 0.000 description 5
208000036443 AIPL1-related retinopathy Diseases 0.000 description 4
108700028369 Alleles Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
206010020751 Hypersensitivity Diseases 0.000 description 4
102100039373 Membrane cofactor protein Human genes 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
206010029113 Neovascularisation Diseases 0.000 description 4
239000002033 PVDF binder Substances 0.000 description 4
206010057249 Phagocytosis Diseases 0.000 description 4
241000219061 Rheum Species 0.000 description 4
102000054727 Serum Amyloid A Human genes 0.000 description 4
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
238000002583 angiography Methods 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
230000007646 directional migration Effects 0.000 description 4
230000003828 downregulation Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000000984 immunochemical effect Effects 0.000 description 4
238000011065 in-situ storage Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000003999 initiator Substances 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
238000013508 migration Methods 0.000 description 4
238000000302 molecular modelling Methods 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
230000008782 phagocytosis Effects 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
229920002981 polyvinylidene fluoride Polymers 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
210000003786 sclera Anatomy 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000005951 type IV hypersensitivity Effects 0.000 description 4
208000027930 type IV hypersensitivity disease Diseases 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
239000011701 zinc Substances 0.000 description 4
XGUFMAUYGBDFJS-UHFFFAOYSA-N 6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1h-naphthalene-8,2'-3h-1-benzofuran]-7'-carboxylic acid Chemical compound C1C(C(=CC(C=O)=C2C(O)=O)O)=C2OC21C1(C)CC(O)C(O)C(C)(C)C1CCC2C XGUFMAUYGBDFJS-UHFFFAOYSA-N 0.000 description 3
102000011767 Acute-Phase Proteins Human genes 0.000 description 3
108010062271 Acute-Phase Proteins Proteins 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
102100030504 Beta-crystallin A4 Human genes 0.000 description 3
101710189772 Beta-crystallin A4 Proteins 0.000 description 3
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
102100020903 Ezrin Human genes 0.000 description 3
108010014173 Factor X Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
102000006354 HLA-DR Antigens Human genes 0.000 description 3
108010058597 HLA-DR Antigens Proteins 0.000 description 3
101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 3
101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
102000004889 Interleukin-6 Human genes 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
102000011782 Keratins Human genes 0.000 description 3
108010076876 Keratins Proteins 0.000 description 3
102100025136 Macrosialin Human genes 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
208000022873 Ocular disease Diseases 0.000 description 3
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 3
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 3
206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 3
208000034461 Progressive cone dystrophy Diseases 0.000 description 3
108010005642 Properdin Proteins 0.000 description 3
102100038567 Properdin Human genes 0.000 description 3
108010053763 Pyruvate Carboxylase Proteins 0.000 description 3
102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
102000012479 Serine Proteases Human genes 0.000 description 3
108010022999 Serine Proteases Proteins 0.000 description 3
108010045517 Serum Amyloid P-Component Proteins 0.000 description 3
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
230000006052 T cell proliferation Effects 0.000 description 3
108700012920 TNF Proteins 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
102000040945 Transcription factor Human genes 0.000 description 3
102000004338 Transferrin Human genes 0.000 description 3
108090000901 Transferrin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
239000012190 activator Substances 0.000 description 3
201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
230000007815 allergy Effects 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
238000000423 cell based assay Methods 0.000 description 3
230000030833 cell death Effects 0.000 description 3
230000006037 cell lysis Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000035605 chemotaxis Effects 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
102000006834 complement receptors Human genes 0.000 description 3
108010047295 complement receptors Proteins 0.000 description 3
201000008615 cone dystrophy Diseases 0.000 description 3
230000008602 contraction Effects 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000003412 degenerative effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000008021 deposition Effects 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
230000004438 eyesight Effects 0.000 description 3
108010055671 ezrin Proteins 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
239000000499 gel Substances 0.000 description 3
210000003630 histaminocyte Anatomy 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
230000005012 migration Effects 0.000 description 3
229930014626 natural product Natural products 0.000 description 3
230000014207 opsonization Effects 0.000 description 3
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 3
210000003668 pericyte Anatomy 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000000649 photocoagulation Effects 0.000 description 3
102000054765 polymorphisms of proteins Human genes 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000011002 quantification Methods 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000008685 targeting Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
230000002792 vascular Effects 0.000 description 3
239000013598 vector Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
206010048998 Acute phase reaction Diseases 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
108010071619 Apolipoproteins Proteins 0.000 description 2
102000007592 Apolipoproteins Human genes 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
102100023995 Beta-nerve growth factor Human genes 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108010009575 CD55 Antigens Proteins 0.000 description 2
108090000549 Calreticulin Proteins 0.000 description 2
102100029968 Calreticulin Human genes 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
208000032544 Cicatrix Diseases 0.000 description 2
241000581364 Clinitrachus argentatus Species 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000004266 Collagen Type IV Human genes 0.000 description 2
108010042086 Collagen Type IV Proteins 0.000 description 2
102000016917 Complement C1 Human genes 0.000 description 2
108010028774 Complement C1 Proteins 0.000 description 2
108700040183 Complement C1 Inhibitor Proteins 0.000 description 2
102000055157 Complement C1 Inhibitor Human genes 0.000 description 2
102100031609 Complement C2 Human genes 0.000 description 2
108090000955 Complement C2 Proteins 0.000 description 2
108010028773 Complement C5 Proteins 0.000 description 2
108010028771 Complement C6 Proteins 0.000 description 2
102000003706 Complement factor D Human genes 0.000 description 2
108090000059 Complement factor D Proteins 0.000 description 2
229940124073 Complement inhibitor Drugs 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
208000003098 Ganglion Cysts Diseases 0.000 description 2
208000008069 Geographic Atrophy Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 2
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000010159 IgA glomerulonephritis Diseases 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
101150046735 LEPR gene Proteins 0.000 description 2
101150063827 LEPROT gene Proteins 0.000 description 2
102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 2
102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
102000003683 Neurotrophin-4 Human genes 0.000 description 2
108090000099 Neurotrophin-4 Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
241000906034 Orthops Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
101100006979 Rattus norvegicus C4 gene Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
208000005400 Synovial Cyst Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004658 acute-phase response Effects 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
230000032683 aging Effects 0.000 description 2
230000004075 alteration Effects 0.000 description 2
206010002022 amyloidosis Diseases 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000002391 anti-complement effect Effects 0.000 description 2
108010008730 anticomplement Proteins 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000006472 autoimmune response Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
150000003937 benzamidines Chemical class 0.000 description 2
102000005735 beta-Crystallins Human genes 0.000 description 2
108010070654 beta-Crystallins Proteins 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000008827 biological function Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
244000309464 bull Species 0.000 description 2
239000007978 cacodylate buffer Substances 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000005482 chemotactic factor Substances 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
238000003759 clinical diagnosis Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000004074 complement inhibitor Substances 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000003413 degradative effect Effects 0.000 description 2
208000022401 dense deposit disease Diseases 0.000 description 2
230000009274 differential gene expression Effects 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000428 dust Substances 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000013534 fluorescein angiography Methods 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
238000003500 gene array Methods 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
238000011194 good manufacturing practice Methods 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
230000001744 histochemical effect Effects 0.000 description 2
210000001822 immobilized cell Anatomy 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000000266 injurious effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
238000011005 laboratory method Methods 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
210000005157 neural retina Anatomy 0.000 description 2
229940097998 neurotrophin 4 Drugs 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
238000011330 nucleic acid test Methods 0.000 description 2
238000002577 ophthalmoscopy Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000007170 pathology Effects 0.000 description 2
238000002823 phage display Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229940067631 phospholipid Drugs 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
210000000608 photoreceptor cell Anatomy 0.000 description 2
239000000049 pigment Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
230000004844 protein turnover Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000010410 reperfusion Effects 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
230000037387 scars Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000002904 solvent Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
230000003614 tolerogenic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
230000008728 vascular permeability Effects 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000002699 waste material Substances 0.000 description 2
238000002424 x-ray crystallography Methods 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
101710125124 14-3-3 protein epsilon Proteins 0.000 description 1
102100025007 14-3-3 protein epsilon Human genes 0.000 description 1
FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
102100031315 AP-2 complex subunit mu Human genes 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
101100055496 Arabidopsis thaliana APP2 gene Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
108700004676 Bence Jones Proteins 0.000 description 1
108050002823 Bestrophin Proteins 0.000 description 1
102000012304 Bestrophin Human genes 0.000 description 1
102100029335 Beta-crystallin A2 Human genes 0.000 description 1
101710189776 Beta-crystallin A2 Proteins 0.000 description 1
102100029334 Beta-crystallin A3 Human genes 0.000 description 1
101710189781 Beta-crystallin A3 Proteins 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
229940123362 C1Q inhibitor Drugs 0.000 description 1
101150071258 C3 gene Proteins 0.000 description 1
102100035793 CD83 antigen Human genes 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241001092081 Carpenteria Species 0.000 description 1
241000499489 Castor canadensis Species 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
208000016615 Central areolar choroidal dystrophy Diseases 0.000 description 1
208000018380 Chemical injury Diseases 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
101710091342 Chemotactic peptide Proteins 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 1
108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 1
208000033810 Choroidal dystrophy Diseases 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
102000002734 Collagen Type VI Human genes 0.000 description 1
108010043741 Collagen Type VI Proteins 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000014447 Complement C1q Human genes 0.000 description 1
108010078043 Complement C1q Proteins 0.000 description 1
108010028780 Complement C3 Proteins 0.000 description 1
102000016918 Complement C3 Human genes 0.000 description 1
108010028776 Complement C7 Proteins 0.000 description 1
108010028777 Complement C8 Proteins 0.000 description 1
102000016916 Complement C8 Human genes 0.000 description 1
108090000044 Complement Factor I Proteins 0.000 description 1
102100037078 Complement component 1 Q subcomponent-binding protein, mitochondrial Human genes 0.000 description 1
101710200389 Complement component 1 Q subcomponent-binding protein, mitochondrial Proteins 0.000 description 1
102100024336 Complement component C7 Human genes 0.000 description 1
102100035431 Complement factor I Human genes 0.000 description 1
101710143772 Complement receptor type 2 Proteins 0.000 description 1
108010003730 Cone Opsins Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
101150021185 FGF gene Proteins 0.000 description 1
229930183931 Filipin Natural products 0.000 description 1
208000001034 Frostbite Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102100039326 Gamma-crystallin S Human genes 0.000 description 1
101710092831 Gamma-crystallin S Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
208000022461 Glomerular disease Diseases 0.000 description 1
206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
206010070476 Haemodialysis complication Diseases 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010006464 Hemolysin Proteins Proteins 0.000 description 1
208000000616 Hemoptysis Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019860 Hereditary angioedema Diseases 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
101000796047 Homo sapiens AP-2 complex subunit mu Proteins 0.000 description 1
101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
101100275686 Homo sapiens CR2 gene Proteins 0.000 description 1
101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 1
101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101001042351 Homo sapiens LIM and senescent cell antigen-like-containing domain protein 1 Proteins 0.000 description 1
101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
101000933607 Homo sapiens Protein BTG3 Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000670189 Homo sapiens Ribulose-phosphate 3-epimerase Proteins 0.000 description 1
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
101000803709 Homo sapiens Vitronectin Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
102000018866 Hyaluronan Receptors Human genes 0.000 description 1
108010013214 Hyaluronan Receptors Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102100029571 Immunoglobulin J chain Human genes 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
102000012355 Integrin beta1 Human genes 0.000 description 1
108010022222 Integrin beta1 Proteins 0.000 description 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
102100020880 Kit ligand Human genes 0.000 description 1
101710177504 Kit ligand Proteins 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102100021754 LIM and senescent cell antigen-like-containing domain protein 1 Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
201000003533 Leber congenital amaurosis Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
208000001344 Macular Edema Diseases 0.000 description 1
206010025415 Macular oedema Diseases 0.000 description 1
208000035719 Maculopathy Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
101710146216 Membrane cofactor protein Proteins 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
101150101095 Mmp12 gene Proteins 0.000 description 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
208000037699 Monosomy 18p Diseases 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100275687 Mus musculus Cr2 gene Proteins 0.000 description 1
101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
108010045503 Myeloma Proteins Proteins 0.000 description 1
102000005717 Myeloma Proteins Human genes 0.000 description 1
108010049175 N-substituted Glycines Proteins 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
206010062212 Neisseria infection Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108700022034 Opsonin Proteins Proteins 0.000 description 1
101150044441 PECAM1 gene Proteins 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108010046016 Peanut Agglutinin Proteins 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102000048176 Prostaglandin-D synthases Human genes 0.000 description 1
108030003866 Prostaglandin-D synthases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
102100026035 Protein BTG3 Human genes 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
206010037457 Pulmonary vasculitis Diseases 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
241000225041 Roestes Species 0.000 description 1
101100016250 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GYL1 gene Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
241000116133 Siphonodictyon coralliphagum Species 0.000 description 1
241001279361 Stachybotrys Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
208000031861 Tritanopia Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
230000021917 activation of membrane attack complex Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940005553 analgesics and anesthetics Drugs 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003324 anti-retinal effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
238000003491 array Methods 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
238000002820 assay format Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
108010014210 axokine Proteins 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
208000009964 basal laminar drusen Diseases 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
229910052790 beryllium Inorganic materials 0.000 description 1
ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
239000003150 biochemical marker Substances 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
201000010018 blue color blindness Diseases 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
230000000981 bystander Effects 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
208000004664 chromosome 18p deletion syndrome Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000003541 chymotrypsin inhibitor Substances 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000000749 co-immunoprecipitation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000002817 coal dust Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000004300 dark adaptation Effects 0.000 description 1
238000001804 debridement Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
108010007093 dispase Proteins 0.000 description 1
210000003027 ear inner Anatomy 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000003352 fibrogenic effect Effects 0.000 description 1
IMQSIXYSKPIGPD-NKYUYKLDSA-N filipin Chemical compound CCCCC[C@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-NKYUYKLDSA-N 0.000 description 1
229950000152 filipin Drugs 0.000 description 1
IMQSIXYSKPIGPD-UHFFFAOYSA-N filipin III Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O IMQSIXYSKPIGPD-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000003348 filter assay Methods 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
238000003117 fluorescence-linked immunosorbent assay Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
238000010448 genetic screening Methods 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
210000000585 glomerular basement membrane Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
108010017007 glucose-regulated proteins Proteins 0.000 description 1
238000001631 haemodialysis Methods 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
230000000322 hemodialysis Effects 0.000 description 1
239000003228 hemolysin Substances 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
150000002411 histidines Chemical class 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000002794 lymphocyte assay Methods 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
208000038015 macular disease Diseases 0.000 description 1
201000010230 macular retinal edema Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
101150035614 mbl-1 gene Proteins 0.000 description 1
201000008350 membranous glomerulonephritis Diseases 0.000 description 1
210000003975 mesenteric artery Anatomy 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
206010062198 microangiopathy Diseases 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000008267 milk Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000037230 mobility Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000009149 molecular binding Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000000651 myofibroblast Anatomy 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
238000001683 neutron diffraction Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000001216 nucleic acid method Methods 0.000 description 1
238000001821 nucleic acid purification Methods 0.000 description 1
230000000050 nutritive effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000012014 optical coherence tomography Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
210000001711 oxyntic cell Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
206010053857 partial lipodystrophy Diseases 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000013930 proline Nutrition 0.000 description 1
150000003148 prolines Chemical class 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
208000025470 retinal cone dystrophy type 1 Diseases 0.000 description 1
210000001116 retinal neuron Anatomy 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
238000009589 serological test Methods 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000000779 smoke Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000011410 subtraction method Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical class FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
150000003588 threonines Chemical class 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000007306 turnover Effects 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
150000003668 tyrosines Chemical class 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000012795 verification Methods 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Ophthalmology & Optometry (AREA)

DK08162987.5T 2000-04-29 2001-04-30 Diagnostik og behandling af makuladegeneration-relaterede forstyrrelser DK2026073T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20069800P	2000-04-29	2000-04-29
EP01934962A EP1287364B1 (en)	2000-04-29	2001-04-30	Diagnostics and therapeutics for macular degeneration-related disorders

Publications (1)

Publication Number	Publication Date
DK2026073T3 true DK2026073T3 (da)	2016-07-25

Family

ID=22742799

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK01934962T DK1287364T3 (da)	2000-04-29	2001-04-30	Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
DK08162987.5T DK2026073T3 (da)	2000-04-29	2001-04-30	Diagnostik og behandling af makuladegeneration-relaterede forstyrrelser

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK01934962T DK1287364T3 (da)	2000-04-29	2001-04-30	Diagnostisk og terapi til makulære degenerationsrelaterede lidelser

Country Status (10)

Country	Link
US (5)	US20020015957A1 (da)
EP (2)	EP2026073B1 (da)
JP (1)	JP4764590B2 (da)
AT (1)	ATE412185T1 (da)
AU (2)	AU6110301A (da)
CA (1)	CA2407715C (da)
DE (1)	DE60136272D1 (da)
DK (2)	DK1287364T3 (da)
ES (1)	ES2316446T3 (da)
WO (1)	WO2001084149A2 (da)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6969601B2 (en)	1997-04-03	2005-11-29	Jensenius Jens Chr	MASP-2, a complement-fixing enzyme, and uses for it
US7108982B1 (en) *	1999-02-19	2006-09-19	University Of Iowa Research Foundation	Diagnostics and the therapeutics for macular degeneration
US20020102581A1 (en) *	1999-02-19	2002-08-01	Hageman Gregory S.	Diagnostics and therapeutics for ocular disorders
US7011952B2 (en) *	2000-02-22	2006-03-14	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
JP4764590B2 (ja) *	2000-04-29	2011-09-07	ユニバーシティーオブアイオワリサーチファウンデーション	黄班変性関連疾患の診断および治療
SE0100595D0 (sv) *	2001-02-22	2001-02-22	Lena Carlsson	Immunological detection of prostate diseases and prostatic-related diseases
US6875165B2 (en)	2001-02-22	2005-04-05	Retinalabs, Inc.	Method of radiation delivery to the eye
US6820011B2 (en)	2001-04-11	2004-11-16	The Regents Of The University Of Colorado	Three-dimensional structure of complement receptor type 2 and uses thereof
AUPS160602A0 (en) *	2002-04-08	2002-05-16	University Of Queensland, The	Therapeutic method
US7354574B2 (en)	2002-11-07	2008-04-08	Advanced Ocular Systems Limited	Treatment of ocular disease
AU2003298650B2 (en) *	2002-11-15	2010-03-11	Musc Foundation For Research Development	Complement receptor 2 targeted complement modulators
JP4269064B2 (ja) *	2003-02-26	2009-05-27	国立大学法人千葉大学	重症筋無力症の検査方法及びそのための検査薬
JPWO2004096277A1 (ja) *	2003-05-01	2006-07-13	国立大学法人京都大学	眼内血管新生疾患の予防又は治療剤
HUE024996T2 (en)	2003-05-12	2016-01-28	Helion Biotech Aps	Anti-MASP-2 antibodies
US7083802B2 (en)	2003-07-31	2006-08-01	Advanced Ocular Systems Limited	Treatment of ocular disease
US7083803B2 (en)	2003-09-19	2006-08-01	Advanced Ocular Systems Limited	Ocular solutions
US7087237B2 (en) *	2003-09-19	2006-08-08	Advanced Ocular Systems Limited	Ocular solutions
BRPI0506629A (pt) *	2004-02-10	2007-05-02	Univ Colorado	inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
EP2298412A1 (en) *	2004-02-12	2011-03-23	Neovista, Inc.	Apparatus for intraocular brachytherapy
US7563222B2 (en) *	2004-02-12	2009-07-21	Neovista, Inc.	Methods and apparatus for intraocular brachytherapy
US20050250745A1 (en) *	2004-02-25	2005-11-10	Seddon Johanna M	Biomarkers for age-related macular degeneration (AMD)
GB0412966D0 (en)	2004-06-10	2004-07-14	Univ Leicester	Genetically modified non-human mammals and cells
US7919094B2 (en)	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
ES2631127T3 (es) *	2004-06-10	2017-08-28	Omeros Corporation	Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
US8840893B2 (en)	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) *	2004-06-10	2006-01-26	University Of Leicester	Methods for treating conditions associated with lectin-dependent complement activation
CA2513317A1 (en)	2004-07-06	2006-01-06	Kuhnil Pharmaceutical Co., Ltd.	Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it
WO2006042252A2 (en)	2004-10-08	2006-04-20	Potentia Pharmeceuticals, Inc.	Viral complement control proteins for eye disorders
US8043609B2 (en)	2004-10-08	2011-10-25	Potentia Pharmaceuticals, Inc.	Viral complement control proteins for eye disorders
JP2008520242A (ja) *	2004-11-18	2008-06-19	イェールユニバーシティ	視覚障害を処置するための方法および組成物
US7745389B2 (en) *	2005-02-14	2010-06-29	University Of Iowa Research Foundation	Methods for treatment of age-related macular degeneration
US20070037183A1 (en) *	2005-03-07	2007-02-15	Trustees Of Boston University	Diagnostic and therapeutic target for macular degeneration
EP1861114B1 (en) *	2005-03-11	2011-02-02	Potentia Pharmaceuticals, Inc.	Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
WO2006128006A1 (en) *	2005-05-26	2006-11-30	The Regents Of The University Of Colorado	Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US20090220953A1 (en) *	2005-08-24	2009-09-03	C.Y.O'connor Erade Village Foundation	Identification of ancestral haplotypes and uses thereof
EP1937706A4 (en) *	2005-09-09	2008-10-22	Univ Iowa Res Found	ORGANIC MARKERS RELATED TO AGE DEPENDENT MAKULAR GENERATION
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2662089A3 (en) *	2005-10-08	2014-02-19	Potentia Pharmaceuticals, Inc.	Compstatin and analogs thereof for eye disorders
SG10201804008UA (en) *	2005-11-04	2018-06-28	Genentech Inc	Use of complement pathway inhibitors to treat ocular diseases
BRPI0618677A2 (pt) *	2005-11-15	2011-09-06	Neovista Inc	métodos e aparelho para braquiterapia intra-ocular
KR20080087814A (ko) *	2005-12-22	2008-10-01	알콘 리서치, 리미티드	보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
US20080146501A1 (en) *	2006-02-13	2008-06-19	University Of Iowa Research Foundation	Protective complement proteins and age-related macular degeneration
WO2007120975A2 (en) *	2006-02-13	2007-10-25	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Variants in complement regulatory genes predict age-related macular degeneration
US8012683B2 (en)	2006-02-13	2011-09-06	University Of Iowa Research Foundation	Variants in complement regulatory genes predict age-related macular degeneration
NZ571791A (en) *	2006-03-08	2012-03-30	Archemix Llc	Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
EP2008101A4 (en) *	2006-04-03	2009-04-29	Univ Iowa Res Found	BINDING OF COMPLEMENT FACTOR H TO C-REACTIVE PROTEIN
US7759304B2 (en)	2006-06-21	2010-07-20	Regents Of The University Of Colorado	Targeting complement factor H for treatment of diseases
EP2479284B1 (en)	2006-07-13	2017-09-20	University of Iowa Research Foundation	Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
EP2054728A2 (en) *	2006-08-23	2009-05-06	University of Iowa Research Foundation	Biomarkers associated with age-related macular degeneration
TW201716437A (zh) *	2006-11-02	2017-05-16	建南德克公司	人類化之抗-因子ｄ抗體及其用途
WO2008091617A2 (en) *	2007-01-23	2008-07-31	Case Western Reserve University	Method for detecting age related macular degeneration in a subject
HUE026001T2 (en) *	2007-02-05	2016-04-28	Apellis Pharmaceuticals Inc	Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
WO2008103299A2 (en)	2007-02-16	2008-08-28	Massachusetts Eye & Ear Infirmary	Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
JP5332064B2 (ja) *	2007-03-01	2013-11-06	ウェルスタットイムノセラピューティクス，エルエルシー	炎症により特徴付けられる疾患の治療
CN101668773B (zh)	2007-03-14	2016-08-31	亚力史制药公司	人工程化抗b因子抗体
US20100015139A1 (en) *	2008-07-10	2010-01-21	Rekha Bansal	METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
CA2680833A1 (en) *	2007-04-30	2008-11-13	Alcon Research, Ltd.	Treatment of age-related macular degeneration using inhibitors of complement factor d
WO2009029784A1 (en) *	2007-08-29	2009-03-05	Novelmed Therapeutics, Inc.	Inhibition of complement and cellular activation
AU2015202046B2 (en) *	2008-02-15	2017-06-29	Tufts University	A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
ES2478820T3 (es) *	2008-02-15	2014-07-23	Tufts University	Tratamiento de degeneración macular
US8114592B2 (en)	2008-03-18	2012-02-14	Cambridge Enterprise Limited	Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
WO2009149175A1 (en)	2008-06-04	2009-12-10	Neovista, Inc.	Handheld radiation delivery system for advancing a radiation source wire
PY09026846A (es)	2008-08-05	2015-09-01	Novartis Ag	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
GB0816702D0 (en) *	2008-09-12	2008-10-22	Trinity College Dublin	Complement proteins
WO2010129351A1 (en) *	2009-04-28	2010-11-11	Schepens Eye Research Institute	Method to identify and treat age-related macular degeneration
US20100291106A1 (en) *	2009-05-06	2010-11-18	Novartis Ag	Compositions and methods for antibodies targeting complement protein c3b
WO2010135717A2 (en)	2009-05-21	2010-11-25	Potentia Pharmaceuticals, Inc.	Complement assays and uses thereof
WO2011003098A1 (en)	2009-07-02	2011-01-06	Musc Foundation For Research Development	Methods of stimulating liver regeneration
CA2781595C (en)	2009-07-10	2016-07-05	The Regents Of The University Of Michigan	Compositions and methods for diagnosing and treating macular degeneration
US20120190578A1 (en) *	2009-08-06	2012-07-26	Washington University	Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
DK2488203T3 (da) *	2009-10-16	2017-03-13	Omeros Corp	Fremgangsmåder til behandling af dissemineret intravaskulær koagulation ved inhibition af masp-2-afhængig komplementaktivering
WO2011053774A1 (en)	2009-10-30	2011-05-05	Alcon Research, Ltd.	Single nucleotide polymorphisms and genes associated with age-related macular degeneration
CA2795311A1 (en)	2009-11-05	2011-05-12	Taligen Therapeutics, Inc.	Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
TR201902542T4 (tr) *	2010-04-13	2019-03-21	M Lab Gmbh	Glokom i̇çi̇n tani yöntemleri̇
BR112012029067A2 (pt)	2010-05-14	2019-09-24	Univ Colorado Regents	grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en)	2010-06-22	2013-01-30	Univ Colorado Regents	Antibodies to the c3d fragment of complement component 3
WO2011163394A2 (en)	2010-06-22	2011-12-29	Apellis Pharmaceuticals, Inc.	Compstatin analogs for treatment of neuropathic pain
CA2843684A1 (en)	2010-08-13	2012-02-16	Tufts University	Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
US20140004510A1 (en)	2010-09-24	2014-01-02	Massachusetts Eye And Ear Infirmary	Methods and compositions for prognosing and/or detecting age-related macular degeneration
US8940490B2 (en)	2010-11-29	2015-01-27	Novelmed Therapeutics, Inc.	Neoantibodies for diagnosing tissue injury
KR101256908B1 (ko)	2011-04-28	2013-04-23	(주)에이치비메디컬스	주름제거용 충전체
ES2728278T3 (es)	2011-12-21	2019-10-23	Novartis Ag	Composiciones que comprenden anticuerpos dirigidos al factor P y C5
US8999292B2 (en)	2012-05-01	2015-04-07	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
AU2013255050B2 (en) *	2012-05-01	2016-07-28	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
US9803005B2 (en)	2012-05-24	2017-10-31	Alexion Pharmaceuticals, Inc.	Humaneered anti-factor B antibody
US10413620B2 (en)	2012-08-17	2019-09-17	The Regents Of The University Of Colorado, A Body Corporate	Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014028861A1 (en) *	2012-08-17	2014-02-20	Apellis Pharmaceuticals, Inc.	Detection of high risk drusen
JP2015535212A (ja)	2012-08-17	2015-12-10	ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト	補体活性化を検出するための組成物および方法
MX366404B (es)	2012-11-15	2019-07-08	Apellis Pharmaceuticals Inc	Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
WO2014151923A1 (en)	2013-03-14	2014-09-25	Baxter International Inc.	Factor h for treatment of rheumatoid arthritis
AU2014236778B2 (en)	2013-03-14	2019-01-03	Baxalta GmbH	Factor H for transplantation
AU2013202965B2 (en)	2013-03-15	2016-07-21	Takeda Pharmaceutical Company Limited	Improved method for producing factor h from a plasma precipitation fraction
WO2014152391A1 (en)	2013-03-15	2014-09-25	Apellis Pharmaceuticals, Inc.	Cell-penetrating compstatin analogs and uses thereof
SG11201601044XA (en)	2013-08-12	2016-03-30	Genentech Inc	Compositions and method for treating complement-associated conditions
CN110724691A (zh)	2014-02-27	2020-01-24	阿勒根公司	补体因子Bb抗体
AU2015253042A1 (en)	2014-05-01	2016-10-20	Genentech, Inc.	Anti-factor D antibody variants and uses thereof
CN107249433B (zh)	2015-03-01	2019-12-20	诺瓦赛特有限公司	用于测量眼能动性的系统和方法
EP3115784A1 (en) *	2015-07-10	2017-01-11	Koss, Michael Janusz	Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases
US11903994B2 (en)	2015-10-07	2024-02-20	Apellis Pharmaceuticals, Inc.	Dosing regimens
US10407510B2 (en)	2015-10-30	2019-09-10	Genentech, Inc.	Anti-factor D antibodies and conjugates
EP3368090A1 (en)	2015-10-30	2018-09-05	H. Hoffnabb-La Roche Ag	Anti-factor d antibody variant conjugates and uses thereof
US20190049465A1 (en) *	2016-02-06	2019-02-14	Georgetown University	Compositions and methods for the diagnosis and treatment of age-related macular degeneration
CN109219386B (zh) *	2016-05-29	2021-06-22	诺瓦赛特有限公司	显示系统和方法
JP6745523B2 (ja) *	2016-08-16	2020-08-26	国立大学法人旭川医科大学	補体系を検査する方法及びそのためのキット
EP3515284B1 (en)	2016-09-23	2023-09-20	Novasight Ltd.	Screening apparatus
EP3529619B1 (en) *	2016-10-19	2021-06-30	Alexion Pharmaceuticals, Inc.	A method of quantitating unbound c5a in a sample
WO2018075758A1 (en) *	2016-10-19	2018-04-26	Alexion Pharmaceuticals, Inc.	A method of quantitating unbound c5 in a sample
IL269844B2 (en)	2017-04-07	2025-01-01	Apellis Pharmaceuticals Inc	Dosage regimens and related compositions and methods
WO2019006153A1 (en) *	2017-06-30	2019-01-03	Anthrobio	IMPROVEMENT OF THE PROTEOLYTIC CASCADE FOR THE TREATMENT OF A DISEASE
EP3655545B1 (en)	2017-07-18	2023-10-18	The Research Foundation for The State University of New York	Biomarkers for intracranial aneurysm
WO2019118938A1 (en)	2017-12-15	2019-06-20	Apellis Pharmaceuticals, Inc.	Dosing regimens and related compositions and methods
WO2020261158A1 (en)	2019-06-25	2020-12-30	Translatum Medicus Inc.	Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
JP2022541851A (ja) *	2019-07-26	2022-09-27	アレグロファーマシューティカルズエルエルシー	眼の非滲出型黄斑変性および他の障害を治療するためのペプチド
US20230243852A1 (en) *	2022-01-26	2023-08-03	Idexx Laboratories, Inc.	Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US102581A (en) *		1870-05-03		Improvement in boiler-furnaces
US3654090A (en)	1968-09-24	1972-04-04	Organon	Method for the determination of antigens and antibodies
US3650090A (en) *	1970-06-19	1972-03-21	Phillips Petroleum Co	Analysis of gaseous mixtures
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
US4517288A (en)	1981-01-23	1985-05-14	American Hospital Supply Corp.	Solid phase system for ligand assay
GB8311018D0 (en)	1983-04-22	1983-05-25	Amersham Int Plc	Detecting mutations in dna
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1291031C (en)	1985-12-23	1991-10-22	Nikolaas C.J. De Jaeger	Method for the detection of specific binding agents and their correspondingbindable substances
US4998617A (en)	1986-09-15	1991-03-12	Laura Lupton Inc	Facial cosmetic liquid make up kit
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5256642A (en)	1988-04-01	1993-10-26	The Johns Hopkins University	Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5506247A (en)	1988-04-15	1996-04-09	T Cell Sciences, Inc.	Compounds that inhibit complement and/or suppress immune activity
US5221616A (en)	1988-07-15	1993-06-22	Quidel Corporation	Prevention of spontaneous complement activation in mammalian biological fluids
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
GB8912497D0 (en)	1989-05-31	1989-07-19	Cobbold Stephen P	Monoclonal antibodies
FR2650840B1 (fr)	1989-08-11	1991-11-29	Bertin & Cie	Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DK0600866T3 (da)	1990-06-01	1998-03-09	Chiron Corp	Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770358A (en)	1991-09-18	1998-06-23	Affymax Technologies N.V.	Tagged synthetic oligomer libraries
KR100310939B1 (ko)	1992-10-01	2002-06-20	추후제출	태그로암호화한복합조합화학라이브러리
DE69433811T2 (de)	1993-01-07	2005-06-23	Sequenom, Inc., San Diego	Dns - sequenzierung durch massenspektronomie
EP0682526B1 (en)	1993-02-12	2002-09-04	Avant Immunotherapeutics, Inc.	PULMONARY ADMINISTRATION OF THE SOLUBLE COMPLEM RECEPTOR TYPE 1 sCR1
WO1995003009A1 (en)	1993-07-22	1995-02-02	Oculex Pharmaceuticals, Inc.	Method of treatment of macular degeneration
US5583973A (en)	1993-09-17	1996-12-10	Trustees Of Boston University	Molecular modeling method and system
US6153203A (en)	1993-10-08	2000-11-28	Duotol Ab	Immunological tolerance-inducing agent
US5681571A (en) *	1993-10-08	1997-10-28	Duotol Ab	Immunological tolerance-inducing agent
BR9407947A (pt)	1993-11-02	1996-11-26	Affymax Tech Nv	Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
AU1441395A (en) *	1993-12-21	1995-07-10	St. Louis University	Ocular diagnostics and therapies
US6140466A (en)	1994-01-18	2000-10-31	The Scripps Research Institute	Zinc finger protein derivatives and methods therefor
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CA2189634A1 (en)	1994-05-06	1995-11-16	John J. Baldwin	Combinatorial dihydrobenzopyran library
GB2290293A (en)	1994-06-08	1995-12-20	Rupert Donald Holms	Preparation which inhibits the autoimmune response in HIV, or SLE, patients
US5663046A (en)	1994-06-22	1997-09-02	Pharmacopeia, Inc.	Synthesis of combinatorial libraries
US5612894A (en)	1995-02-08	1997-03-18	Wertz; David H.	System and method for molecular modeling utilizing a sensitivity factor
US6103235A (en)	1995-10-30	2000-08-15	The United States Of America As Represented By The Department Of Health And Human Services	Methods of inducing immune tolerance using immunotoxins
JPH09194393A (ja)	1996-01-22	1997-07-29	Meiji Milk Prod Co Ltd	免疫寛容を誘導する方法、免疫寛容誘導食品キットおよび免疫寛容誘導剤キット
EP0888459A1 (en)	1996-02-02	1999-01-07	Stichting Onderzoeksbeleid Cardiopulmonale Chirurgie	Measurement of complement activation by biomaterials by means of complement convertase cleavage of peptide substrates
UA66757C2 (en)	1996-02-26	2004-06-15	Advanced Res & Tech Inst	Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
US5843449A (en)	1996-03-25	1998-12-01	Akzo Nobel N.V.	Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5705380A (en) *	1996-09-04	1998-01-06	Sequana Theraputics, Inc.	Identification of a gene encoding TULP2, a retina specific protein
US5686598A (en) *	1996-08-22	1997-11-11	The Jackson Laboratory	Genes associated with retinal dystrophies
CA2251603A1 (en)	1996-04-10	1997-10-16	Axys Pharmaceuticals, Inc.	Gene family associated with neurosensory defects
US6102236A (en) *	1997-01-31	2000-08-15	Tetra Laval Holdings & Finance S.A.	Lid of a container for beverages
US5773673A (en) *	1997-07-01	1998-06-30	Occidental Chemical Corporation	Method of making chlorinated hydrocarbons
DE69829402T2 (de)	1997-10-31	2006-04-13	Affymetrix, Inc. (a Delaware Corp.), Santa Clara	Expressionsprofile in adulten und fötalen organen
US6956107B2 (en) *	1998-02-20	2005-10-18	Tanox, Inc.	Inhibitors of complement activation
US6015803A (en)	1998-05-04	2000-01-18	Wirostko; Emil	Antibiotic treatment of age-related macular degeneration
US20020102581A1 (en)	1999-02-19	2002-08-01	Hageman Gregory S.	Diagnostics and therapeutics for ocular disorders
US20030149997A1 (en) *	1999-02-19	2003-08-07	Hageman Gregory S.	Diagnostics and therapeutics for arterial wall disruptive disorders
US7108982B1 (en) *	1999-02-19	2006-09-19	University Of Iowa Research Foundation	Diagnostics and the therapeutics for macular degeneration
EP1161686A2 (en)	1999-03-05	2001-12-12	University Of Iowa Research Foundation	Diagnostics and therapeutics for drusen associated ocular disorders
US7011952B2 (en) *	2000-02-22	2006-03-14	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
JP4764590B2 (ja)	2000-04-29	2011-09-07	ユニバーシティーオブアイオワリサーチファウンデーション	黄班変性関連疾患の診断および治療
TW201716437A (zh) *	2006-11-02	2017-05-16	建南德克公司	人類化之抗-因子ｄ抗體及其用途
EP2158330A2 (en) *	2007-05-11	2010-03-03	Tufts Medical Center	Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
AR066660A1 (es) *	2007-05-23	2009-09-02	Genentech Inc	Prevencion y tratamiento de condiciones del ojo asociadas con su complemento

2001
- 2001-04-30 JP JP2001581122A patent/JP4764590B2/ja not_active Expired - Fee Related
- 2001-04-30 EP EP08162987.5A patent/EP2026073B1/en not_active Expired - Lifetime
- 2001-04-30 EP EP01934962A patent/EP1287364B1/en not_active Expired - Lifetime
- 2001-04-30 DK DK01934962T patent/DK1287364T3/da active
- 2001-04-30 AT AT01934962T patent/ATE412185T1/de not_active IP Right Cessation
- 2001-04-30 ES ES01934962T patent/ES2316446T3/es not_active Expired - Lifetime
- 2001-04-30 WO PCT/US2001/013971 patent/WO2001084149A2/en not_active Ceased
- 2001-04-30 DK DK08162987.5T patent/DK2026073T3/da active
- 2001-04-30 AU AU6110301A patent/AU6110301A/xx active Pending
- 2001-04-30 AU AU2001261103A patent/AU2001261103B2/en not_active Ceased
- 2001-04-30 US US09/845,745 patent/US20020015957A1/en not_active Abandoned
- 2001-04-30 CA CA002407715A patent/CA2407715C/en not_active Expired - Fee Related
- 2001-04-30 DE DE60136272T patent/DE60136272D1/de not_active Expired - Lifetime
2003
- 2003-04-18 US US10/419,305 patent/US7351524B2/en not_active Expired - Lifetime
2006
- 2006-05-30 US US11/443,696 patent/US20060263819A1/en not_active Abandoned
2010
- 2010-09-23 US US12/889,311 patent/US20110182908A1/en not_active Abandoned
2018
- 2018-02-15 US US15/897,609 patent/US20180335436A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2001261103B2 (en)	2007-08-23
US20060263819A1 (en)	2006-11-23
WO2001084149A3 (en)	2002-07-18
ATE412185T1 (de)	2008-11-15
EP1287364B1 (en)	2008-10-22
CA2407715C (en)	2009-03-24
US20110182908A1 (en)	2011-07-28
DE60136272D1 (de)	2008-12-04
WO2001084149A2 (en)	2001-11-08
JP2003535581A (ja)	2003-12-02
EP1287364A2 (en)	2003-03-05
US20020015957A1 (en)	2002-02-07
US7351524B2 (en)	2008-04-01
EP2026073A1 (en)	2009-02-18
EP2026073B1 (en)	2016-03-30
AU6110301A (en)	2001-11-12
JP4764590B2 (ja)	2011-09-07
US20030207309A1 (en)	2003-11-06
ES2316446T3 (es)	2009-04-16
US20180335436A1 (en)	2018-11-22
DK1287364T3 (da)	2009-03-02
CA2407715A1 (en)	2001-11-08

Publication	Publication Date	Title
DK2026073T3 (da)	2016-07-25	Diagnostik og behandling af makuladegeneration-relaterede forstyrrelser
AU2001261103A1 (en)	2002-01-31	Diagnostics and therapeutics for macular degeneration-related disorders
US7682804B2 (en)	2010-03-23	Diagnostics and therapeutics for macular degeneration-related disorders
US20070274921A1 (en)	2007-11-29	Diagnostics and therapeutics for ocular disorders
EP1153302B1 (en)	2006-10-25	Diagnostics and therapeutics for macular degeneration
US20030149997A1 (en)	2003-08-07	Diagnostics and therapeutics for arterial wall disruptive disorders
US20080274453A1 (en)	2008-11-06	Diagnostics and therapeutics for macular degeneration
CA2363503C (en)	2009-03-10	Diagnostics and therapeutics for drusen associated ocular disorders
WO2003050137A2 (en)	2003-06-19	Toll-like receptor 4 mutations
US20200338039A1 (en)	2020-10-29	Methods and materials for assessing biological age and slowing the progress of excessive biological aging
EP2795337B1 (en)	2017-12-20	Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
Harris et al.	2025	The Role of Inflammation in Age-Related Macular Degeneration
Hageman et al.	2008	lowa Research Online
US20070031833A1 (en)	2007-02-08	Method For Examining Obesity Or Leanness
WO2025058047A1 (ja)	2025-03-20	補体関連疾患を検査する方法